• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

培美曲塞治疗非小细胞肺癌后间质性肺炎。

Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.

机构信息

Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea.

出版信息

Cancer Res Treat. 2013 Mar;45(1):74-7. doi: 10.4143/crt.2013.45.1.74. Epub 2013 Mar 31.

DOI:10.4143/crt.2013.45.1.74
PMID:23613674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3629367/
Abstract

Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.

摘要

培美曲塞已被批准与顺铂联合用于治疗晚期非鳞状非小细胞肺癌（NSCLC），也可作为二线治疗药物，或用于铂类双药诱导化疗 4 个周期后无疾病进展的患者作为维持治疗。培美曲塞的毒性谱适中，传统上不被认为是间质性肺炎的病因。在此，我们报告了一例 NSCLC 患者使用培美曲塞引起的肺炎的罕见病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b81/3629367/19d9c56a0652/crt-45-74-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b81/3629367/e03e1441508f/crt-45-74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b81/3629367/19d9c56a0652/crt-45-74-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b81/3629367/e03e1441508f/crt-45-74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b81/3629367/19d9c56a0652/crt-45-74-g002.jpg

相似文献

1
Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.培美曲塞治疗非小细胞肺癌后间质性肺炎。
Cancer Res Treat. 2013 Mar;45(1):74-7. doi: 10.4143/crt.2013.45.1.74. Epub 2013 Mar 31.
2
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?晚期非小细胞肺癌（NSCLC）：是否所有患者都需要维持治疗？
Curr Treat Options Oncol. 2012 Dec;13(4):478-90. doi: 10.1007/s11864-012-0209-1.
3
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.培美曲塞联合最佳支持治疗维持治疗对比安慰剂联合最佳支持治疗用于培美曲塞联合顺铂诱导治疗后的晚期非鳞状非小细胞肺癌（PARAMOUNT）：一项双盲、III 期、随机对照临床试验。
Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16.
4
Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.培美曲塞-铂类双药化疗联合或不联合贝伐珠单抗作为中国未经治疗的晚期非鳞状非小细胞肺癌患者一线治疗的疗效比较。
Clin Ther. 2019 Mar;41(3):518-529. doi: 10.1016/j.clinthera.2019.02.004. Epub 2019 Mar 4.
5
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis.培美曲塞持续维持治疗与传统铂类双药化疗用于表皮生长因子受体阴性肺腺癌的回顾性分析
Tuberc Respir Dis (Seoul). 2018 Apr;81(2):148-155. doi: 10.4046/trd.2017.0090. Epub 2018 Mar 7.
6
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.晚期非鳞状非小细胞肺癌患者在顺铂、培美曲塞和贝伐珠单抗诱导治疗后行多西他赛和贝伐珠单抗维持治疗的 II 期研究。
Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x.
7
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.培美曲塞单药与非培美曲塞铂类双药方案作为一线表皮生长因子受体（EGFR）酪氨酸激酶抑制剂治疗失败后的二线化疗用于EGFR突变的非小细胞肺癌患者。
Cancer Res Treat. 2015 Oct;47(4):630-7. doi: 10.4143/crt.2014.244. Epub 2015 Feb 16.
8
Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).在一线使用非铂类方案预处理的非小细胞肺癌患者中，伊立替康/顺铂与培美曲塞/顺铂挽救治疗的比较：希腊肿瘤学研究组（HORG）的一项随机II期研究
Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.
9
Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.铂类-长春瑞滨诱导化疗联合贝伐单抗在晚期非小细胞肺癌中应用或不应用培美曲塞序贯维持治疗
Anticancer Res. 2015 Nov;35(11):6255-9.
10
[Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].[组织学对培美曲塞疗效的影响：中国晚期非小细胞肺癌患者二线应用培美曲塞及一线治疗后维持治疗的情况]
Zhonghua Zhong Liu Za Zhi. 2014 Jan;36(1):29-33.

引用本文的文献

1
Radiation induced lung injury (RILI) after postoperative intensity modulated proton therapy (IMPT) in a patient with stage III locally advanced lung adenocarcinoma: a case report.III期局部晚期肺腺癌患者术后调强质子治疗（IMPT）后发生放射性肺损伤（RILI）：一例报告
Transl Cancer Res. 2022 Sep;11(9):3400-3408. doi: 10.21037/tcr-22-256.
2
Pemetrexed Induced Life-threatening Anaphylaxis.培美曲塞诱发危及生命的过敏反应。
Cureus. 2019 Aug 29;11(8):e5514. doi: 10.7759/cureus.5514.
3
Pemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case.

本文引用的文献

1
A case of pemetrexed-induced acute lung injury in non-small cell lung cancer.培美曲塞引起的非小细胞肺癌急性肺损伤1例。
J Thorac Oncol. 2010 Mar;5(3):401-2. doi: 10.1097/JTO.0b013e3181c5b198.
2
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.培美曲塞维持治疗联合最佳支持治疗与安慰剂联合最佳支持治疗用于非小细胞肺癌：一项随机、双盲、3期研究
Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5. Epub 2009 Sep 18.
3
Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
培美曲塞诱导的类似过敏性肺炎的间质性肺疾病：一例病理证实病例
Intern Med. 2019 Sep 15;58(18):2679-2682. doi: 10.2169/internalmedicine.2548-18. Epub 2019 Jun 7.
4
Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review.培美曲塞诱导的间质性肺炎：一例病例研究及文献综述
World J Oncol. 2014 Dec;5(5-6):232-236. doi: 10.14740/wjon845w. Epub 2014 Dec 3.
5
Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.自噬抑制增强培美曲塞和辛伐他汀诱导的恶性间皮瘤和非小细胞肺癌细胞凋亡性细胞死亡。
Oncotarget. 2015 Oct 6;6(30):29482-96. doi: 10.18632/oncotarget.5022.
6
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.培美曲塞用于治疗患有间质性肺疾病的晚期非小细胞肺癌患者。
BMC Cancer. 2014 Jul 10;14:508. doi: 10.1186/1471-2407-14-508.
培美曲塞作为非小细胞肺癌三线治疗的疗效与毒性
Jpn J Clin Oncol. 2009 Jan;39(1):27-32. doi: 10.1093/jjco/hyn118. Epub 2008 Oct 24.
4
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.两剂培美曲塞联合叶酸和维生素B12用于既往治疗过的非小细胞肺癌患者的疗效和安全性
Clin Cancer Res. 2008 Jul 1;14(13):4206-12. doi: 10.1158/1078-0432.CCR-07-5143.
5
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.一项III期研究，比较顺铂加吉西他滨与顺铂加培美曲塞用于初治晚期非小细胞肺癌患者的化疗效果。
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
6
Diagnosis and management of drug-associated interstitial lung disease.药物相关性间质性肺疾病的诊断与管理
Br J Cancer. 2004 Aug;91 Suppl 2(Suppl 2):S24-30. doi: 10.1038/sj.bjc.6602064.
7
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.培美曲塞与多西他赛用于既往接受过化疗的非小细胞肺癌患者的随机III期试验。
J Clin Oncol. 2004 May 1;22(9):1589-97. doi: 10.1200/JCO.2004.08.163.